Identification of a Novel Target for the Treatment of Endometriosis-associated Pain
确定治疗子宫内膜异位症相关疼痛的新靶点
基本信息
- 批准号:10508963
- 负责人:
- 金额:$ 26.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-15 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:ARNT geneAbdominal PainAffectAffinityAgonistAmericanArrestinsBiological AssayCD59 AntigenCellsChronic DiseaseClinical ResearchDataDevelopmentDiseaseDrug KineticsDrug TargetingEndometriumEstrogen ReceptorsExhibitsFDA approvedFamilyFemale of child bearing ageFiberFriendsFunctional disorderG-Protein-Coupled ReceptorsGTP-Binding Protein alpha Subunits, GsGTP-Binding ProteinsGene ExpressionGene Expression ProfileGenesGrowthHealth Care CostsHemosiderinHormonalHumanHuman GenomeImmuneInfertilityInflammatoryKnockout MiceKnowledgeLaboratoriesLeadLesionLibrariesLipidsMeasuresMediatingMediator of activation proteinMethodologyModelingMolecularNon-Steroidal Anti-Inflammatory AgentsOperative Surgical ProceduresPainPatientsPelvic PainPharmaceutical PreparationsProgram DevelopmentPropertyPublishingReceptor CellRegimenResourcesSamplingSignal TransductionStimulusStructureSumSurveysSystemTestingTherapeuticTissuesUp-RegulationValidationWomanWorkantagonistcell typechild bearingchronic pelvic paincostcost estimateendometriosisexperienceexperimental studyfollow-uphigh throughput screeninghuman diseasein vivoknock-downlipid mediatormouse modelnew therapeutic targetnovelnovel therapeuticsoverexpressionpain reliefpharmacodynamic biomarkerpharmacophorepreclinical studyreceptorreceptor expressionscreeningside effectsingle-cell RNA sequencingsuccesstherapeutic developmenttoolunpublished works
项目摘要
Endometriosis is an inflammatory disease characterized by the presence of endometrium-like lesions and
progressive abdominal or pelvic pain. It affects ~10% of women of childbearing age and ~30% of patients are
not effectively treated by existing options; new therapeutics are desperately needed. We have developed and
validated a mouse model of endometriosis pain. Using that model, we discovered that the specific pro-
resolving lipid mediator (SPM) protectin DX (PDX) rapidly abolishes endometriosis-associated pain and shrinks
lesions. Unfortunately, poor stability and pharmacokinetic properties render PDX a poor drug lead. To
leverage the anti-endometriosis activity of PDX, its receptor must be identified. All SPMs for which a high
affinity receptor is known activate G-protein coupled receptors (GPCRs). Thus we hypothesize that PDX acts
through a GPCR and aim to identify it and the cell type(s) expressing the PDX receptor.
We will identify the mechanism by which protectin DX acts by using the PRESTO-Tango system to
measure arrestin activation in a comprehensive library of human non-olfactory GPCRs. We will then identify
the G-protein(s) that couple to this GPCR in the context of PDX signaling. To confirm that this is the relevant
receptor, we will measure the effect of ablating this GPCR on the PDX-mediated increase in efferocytosis and
up regulation of M2 markers in RAW264.7 cells. Next, we will seek to identify the cell types that mediate the
anti-endometriosis effects of multiple SPMs, including MaR1, RvD5, and PDX. To that end, we will use single-
cell RNAseq (scRNAseq) to identify cell types that express SPM receptors in our mouse model of
endometriosis-associated pain at a relevant timepoint. We will also measure the effect of PDX on the
transcriptional profile of relevant cell types in vivo, in order to begin to understand how PDX relieves pain and
reduces lesion size. Then, we will use available resources to confirm expression of these receptors in cells
human lesions.
When these experiments are complete, we will have identified a novel, druggable target for endometriosis
therapy. As this is expected to be a GPCR, common strategies like high-throughput screening (with which we
have experience) can then be used to identify pharmacophores that lack the liabilities present in PDX, itself.
We will also identify pharmacodynamic markers of protectin DX activity that will allow target engagement to be
measured during a therapeutic development program. Although additional target validations work (e.g. with
knockout mice) will remain, these studies will provide important knowledge about the mechanism by which
SPMs, including PDX, reduce endometriosis-associated pain and lesion growth. Thus, the knowledge to be
gained by these studies will represent an important advance toward the development of desperately needed
novel therapeutics for endometriosis.
子宫内膜异位症是一种炎症性疾病,其特征是存在子宫内膜样病变和
进行性腹部或骨盆疼痛。它影响约10%的育龄妇女,约30%的患者是
没有现有选择有效治疗;迫切需要新的治疗剂。我们已经开发了
验证了子宫内膜异位疼痛的小鼠模型。使用该模型,我们发现特定的亲
解决脂质介质(SPM)保护素DX(PDX)迅速废除子宫内膜异位相关的疼痛和收缩
病变。不幸的是,稳定性和药代动力学特性差使PDX成为较差的药物铅。到
必须鉴定出PDX的抗内膜异位性活性,必须鉴定出其受体。所有的SPM
亲和受体已知激活G蛋白偶联受体(GPCR)。因此,我们假设PDX作用
通过GPCR并旨在识别它和表达PDX受体的细胞类型。
我们将确定通过使用presto-tango系统来保护蛋白DX的机制
在人类非野性GPCR的综合库中测量逮捕蛋白激活。然后我们将确定
在PDX信号传导的背景下,夫妇与该GPCR的G蛋白。确认这是相关的
受体,我们将衡量消融该GPCR对PDX介导的递增细胞增多症的增加和
加强RAW264.7细胞中M2标记的调节。接下来,我们将寻求确定介导的细胞类型
多个SPM的抗内膜异位作用,包括MAR1,RVD5和PDX。为此,我们将使用单一
细胞RNASEQ(SCRNASEQ)识别在我们的小鼠模型中表达SPM受体的细胞类型
在相关时间点上与子宫内膜异位相关的疼痛。我们还将测量PDX对
相关细胞类型体内的转录曲线,以便开始了解PDX如何缓解疼痛和
减小病变大小。然后,我们将使用可用资源来确认这些受体在细胞中的表达
人体病变。
这些实验完成后,我们将确定一个新型的可吸毒目标用于子宫内膜异位症
治疗。因为这预计将是GPCR,诸如高通量筛查之类的常见策略(我们与之
然后可以使用经验)来识别缺乏PDX本身中存在的负债的药算团。
我们还将确定保护蛋白DX活动的药效学标记,这将使目标参与成为
在治疗开发计划中测量。尽管其他目标验证有效(例如
敲除小鼠)将保留,这些研究将提供有关机制的重要知识
包括PDX在内的SPM减少子宫内膜异位症相关的疼痛和病变生长。因此,知识成为
这些研究获得的将代表着迫切需要发展的重要进步
用于子宫内膜异位症的新型疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL SEAN ROGERS其他文献
MICHAEL SEAN ROGERS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL SEAN ROGERS', 18)}}的其他基金
Functional requirement of CMG2 for endothelial cell chemotaxis and resulting angiogenesis
CMG2 内皮细胞趋化性和由此产生的血管生成的功能要求
- 批准号:
10522258 - 财政年份:2022
- 资助金额:
$ 26.55万 - 项目类别:
Identification of a Novel Target for the Treatment of Endometriosis-associated Pain
确定治疗子宫内膜异位症相关疼痛的新靶点
- 批准号:
10705085 - 财政年份:2022
- 资助金额:
$ 26.55万 - 项目类别:
Functional requirement of CMG2 for endothelial cell chemotaxis and resulting angiogenesis
CMG2 内皮细胞趋化性和由此产生的血管生成的功能要求
- 批准号:
10705632 - 财政年份:2022
- 资助金额:
$ 26.55万 - 项目类别:
CMG2 as a target for safe and effective treatment of endometriosis-associate pain
CMG2 作为安全有效治疗子宫内膜异位症相关疼痛的靶点
- 批准号:
10583339 - 财政年份:2022
- 资助金额:
$ 26.55万 - 项目类别:
Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors
针对炭疽毒素受体的新型血管生成抑制剂
- 批准号:
7615664 - 财政年份:2008
- 资助金额:
$ 26.55万 - 项目类别:
Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors
针对炭疽毒素受体的新型血管生成抑制剂
- 批准号:
8068796 - 财政年份:2008
- 资助金额:
$ 26.55万 - 项目类别:
Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors
针对炭疽毒素受体的新型血管生成抑制剂
- 批准号:
8268448 - 财政年份:2008
- 资助金额:
$ 26.55万 - 项目类别:
Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors
针对炭疽毒素受体的新型血管生成抑制剂
- 批准号:
8072400 - 财政年份:2008
- 资助金额:
$ 26.55万 - 项目类别:
Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors
针对炭疽毒素受体的新型血管生成抑制剂
- 批准号:
7436075 - 财政年份:2008
- 资助金额:
$ 26.55万 - 项目类别:
Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors
针对炭疽毒素受体的新型血管生成抑制剂
- 批准号:
7813810 - 财政年份:2008
- 资助金额:
$ 26.55万 - 项目类别:
相似国自然基金
肠易激综合征(IBS)腹痛的细胞和分子机制研究
- 批准号:81971046
- 批准年份:2019
- 资助金额:55 万元
- 项目类别:面上项目
中枢介导的腹痛综合征患者大脑多模态磁共振成像研究
- 批准号:81800482
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
疏肝健脾法通过调控组蛋白乙酰化修饰降低肝郁脾虚IBS-D内脏高敏感的机制研究
- 批准号:81703955
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
基于PKCγ/ERK1/2/MAPK信号通路探讨安肠汤缓解腹泻型肠易激综合征腹痛研究
- 批准号:81560754
- 批准年份:2015
- 资助金额:39.0 万元
- 项目类别:地区科学基金项目
针刺治疗功能性消化不良上腹痛综合征的疼痛记忆淡化机制研究
- 批准号:81473602
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
相似海外基金
The Injectrode- An injectable, easily removable electrode as a trial lead for baroreceptor activation therapy to treat hypertension and heart failure
Injectrode——一种可注射、易于拆卸的电极,作为压力感受器激活疗法的试验引线,以治疗高血压和心力衰竭
- 批准号:
10697600 - 财政年份:2023
- 资助金额:
$ 26.55万 - 项目类别:
The Role of Sleep in the Relationships Among Adverse Childhood Experiences, Mental Health Symptoms, and Persistent/Recurrent Pain during Adolescence
睡眠在不良童年经历、心理健康症状和青春期持续/复发性疼痛之间关系中的作用
- 批准号:
10676403 - 财政年份:2023
- 资助金额:
$ 26.55万 - 项目类别:
Dietary regulation of type 2 immunity and inflammation in the gut
肠道 2 型免疫和炎症的饮食调节
- 批准号:
10740269 - 财政年份:2023
- 资助金额:
$ 26.55万 - 项目类别:
New Therapy for the Treatment of Primary Biliary Cholangitis.
治疗原发性胆汁性胆管炎的新疗法。
- 批准号:
10697484 - 财政年份:2023
- 资助金额:
$ 26.55万 - 项目类别:
Disrupted sleep architecture in adolescents with functional abdominal pain disorders
患有功能性腹痛疾病的青少年的睡眠结构被破坏
- 批准号:
10641146 - 财政年份:2023
- 资助金额:
$ 26.55万 - 项目类别: